Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Medicenna Therapeutics Corp. has unveiled promising preclinical data from its BiSKIT and IL-2 Super Agonist programs, showcasing potential breakthroughs in cancer treatment. Their novel therapies, MDNA113 and MDNA11, have demonstrated significant tumor regression and survival benefits in aggressive cancer models, promising hope for millions affected by tumors worldwide.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.